axicabtagene ciloleucel
daiichi sankyo,gilead
['dlbcl', 'axi-cel', ' ipi ', 'elevate,(-elevate uc),(-elevateuc),(-elevate-uc),(-elevate rr),(-elevaterr),(-elevate-rr),(-elevate tn),(-elevatetn),(-elevate-tn)', 'lymphoma', 'lymsm']
no impact of double hit status on outcome post car-t in r/r dlbcl: jurko et al
- us retrosp study
- 80 dhl pts, most had axi-cel, 328 non-dhl
- no diff pfs/os seen
- post-pd, dhl did much worse with far less enrolment on trials
underscores early use of car-t in dhl
#ash22 #lymsm 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.